LENSAR director sells 22,214 and 10,961 shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
LENSAR, Inc. director Elizabeth G. O'Farrell exercised options for 22,214 shares at $3.23 and sold those shares on November 17, 2026, at a weighted average of $5.20 per share (sales ranged from $5.00 to $5.285). On November 18, 2026, she exercised options for 10,961 shares at $3.23 and sold those shares at a weighted average of $4.97 per share (sales ranged from $4.96 to $4.97). No Rule 10b5-1 plan is reported.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) F3 | 10,961 | $0.00 | $0.00 |
| Exercise | Common Stock | 10,961 | $3.23 | $35K |
| Sale | Common Stock F2 | 10,961 | $4.97 | $54K |
| Exercise | Stock Option (Right to Buy) F3 | 22,214 | $0.00 | $0.00 |
| Exercise | Common Stock | 22,214 | $3.23 | $72K |
| Sale | Common Stock F1 | 22,214 | $5.20 | $116K |
Footnotes (3)
- F1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.00 to $5.285. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.96 to $4.97. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F3. The option vested in twelve (12) substantially equal monthly installments commencing June 25, 2023, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date. The option was granted in accordance with the Issuer's non-employee director compensation program as a component of the Reporting Person's annual compensation for service to the Issuer.
Key Figures
Key Terms
weighted average price financial
vesting financial
non-employee director compensation program financial
Rule 10b5-1 plan regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What were the terms of Elizabeth G. O'Farrell's LNSR options?
AI-generated analysis. How Rhea-AI works. Not financial advice.